Feeds:
Posts
Comments

Posts Tagged ‘Glaxosmithkline’

Teva aggressively seeking to “genericize” Merck‘s Singulair, Amgen‘s Neupogen.

Warren Buffet pulling back from pharma investments that contain 2 letters (P&G, J&J).

GSK‘s nausea drug Zofran may help with drug withdrawal symptomsGlaxoSmithKline Plc’s Zofran, approved to treat nausea and vomiting, appears to reduce symptoms of withdrawal from morphine, codeine, heroin, OxyContin and similar pain medicines, a study shows. The drug, which is now available as a generic called ondansetron, was used to treat eight men for morphine withdrawal, according to a study in the Journal of Pharmacogenetics and Genomics. Compared with placebo, the patients receiving ondansetron were less likely to experience anxiety, hot flashes, aches, restlessness, nausea and vomiting.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Reblog this post [with Zemanta]

Read Full Post »

The FDA gives a hint of hope for the long-delayed Eli Lilly/Daiichi Sankyo drug prasugrel. Burrow deep inside this 357-page FDA document just posted online, and you’ll find this jargony but significant sentence: The Division recommends approval of prasugrel for reduction of myocardial infarction in patients with ACS who are managed with PCI.

Glaxo the latest Big Pharma to announce major upcoming cutsBritish drugs company GlaxoSmithKline Plc.  is set to announce about 6,000 job losses when it posts results on Thursday, the Sunday Telegraph newspaper said. The cuts by Glaxo, the world’s second largest drugs company after U.S. group Pfizer, are part of Chief Executive Andrew Witty’s strategy to meet the challenges facing the industry, including increased competition from generic drug makers, the British newspaper said.

Teva gets FDA OK for generic version of J&J‘s Risperdal. And, Takeda gets approval for new GERD drug Kapidex.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Reblog this post [with Zemanta]

Read Full Post »

Glaxo: more big cuts, and the U.S. HQ needle pointing south – GlaxoSmithKline (GSK) announced that it will reduce its sales personnel by 12% to 7,500 down from 8,500. The company will slash 1,800 jobs resulting in a total of 1,000 layoffs. Some positions have already been eliminated while other personnel will be reassigned to new areas. The company is also consolidating operations and moving personnel from its Philadelphia facility to Research Triangle Park in North Carolina, where it employs about 5,000 people…more

Gilead gets a boost from new HIV treatment guidelines – The DHHS named Gilead’s Truvada, a combination of the company’s HIV treatments Emtriva and Viread, the lone preferred regimen for previously untreated HIV patients. Gilead’s shares added 3.2% to $47.31 in regular trading…more

Genzyme pours serious cash into Osiris – Genzyme Corp. will pay Osiris Therapeutics Inc. as much as $1.38 billion to develop therapies that use stem cells to treat blood cancers, inflammation and joint damage. ..more

Amylin’s Byetta LAR gets extended delay for extended release – Shares of Amylin Pharmaceuticals have collapsed after it emerged that US regulators have rejected data for a once-weekly version of its diabetes drug Byetta…more

UCB gets OAB drug approval – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved the anti-muscarinic agent Toviaz® (fesoterodine fumarate) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency…more

What does Jupiter have to do with cholesterol treatments? A lot!

But will Winnie be used to sell obesity treatments? Pooh characters as Seroquel sales aids? Hmmm…

Cephalon’s Treanda gets another indication – on Friday received a second approval from the Food and Drug Administration for its cancer drug Treanda, this time as a treatment for patients with non-Hodgkins lymphoma (NHL)…more

CV Therapeutics’ Ranexa gets a first-line approval – CV Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa® (ranolazine extended-release tablets) for the treatment of chronic angina. The new labeling also provides information showing that Ranexa reduced arrhythmias including ventricular arrhythmias, new onset atrial fibrillation and a potentially dangerous slow heartbeat known as bradycardia in patients with coronary artery disease. In addition, the new labeling states that Ranexa reduces hemoglobin A1c (HbA1c) in patients with diabetes…more

Promising experimental Hep-C treatment in the Schering pipeline – results being reported.

Obesity drugs: everybody bails out – For those of you hoping that America’s obesity crisis could be solved with a pill, think again. Pfizer announced late Wednesday that it is scrapping its anti-fat drug, the as-yet unnamed “CP-945,598,” for essentially political reasons. Sanofi-Aventis today also announced that it was ending its trials on Acomplia/Zimulti, an obesity pill that was approved and then yanked in Europe. And Merck a couple of weeks ago pulled its fat pill taranabant, from its pipeline…more

Why did J&J consolidate its drug advertising biz between 2 big agency holding companies?

Big Pharma’s loss may be Little Pharma’s gain – as big drugmakers continue to trim jobs, smaller biopharmaceutical makers and specialty pharma are benefiting from the downsizing, according to David Poling, director of state business operations at Aerotek, a staffing firm…more

The 10 weirdest drug stories of the month.

First glimpse of the secrets of the cancer genome. Fascinating.

If you’re not up on the latest pharma/legal issue called pre-emption, you need to be. Go here for the latest.

Want even more news? Chris Truelove over at Pharmalive has a big roundup this week – lots of interesting tidbits and links..

Reblog this post [with Zemanta]

Read Full Post »

Huge cuts at Schering-Plough: 1,000 sales jobs going away – As part of a reorganization already under way, the drugmaker is eliminating 1,000 sales jobs – or 20 percent of its sales force – by October. Many of the 4,000 or so surviving reps, meanwhile, will be shifted to pitch different types of docs or work in other territories. A Schering-Plough spokesman confirmed the cuts…more

New Roche arthritis biologic delayed – In a setback for the drugmaker, the agency has issued a ‘complete response’ letter for Actemra, a biologic Roche hopes to market for treating rheumatoid arthritis. An FDA advisory committee endorsed its use last July by a 10-1 vote, but the agency wants “additional documentation” about manufacturing and other unspecified info, some of which relates to final labeling, according to Roche…more

Merck’s Gardasil: OK for vaginal cancer – U.S. health regulators have approved Merck and Co’s Gardasil vaccine to protect women against rare vaginal and vulvar cancers, the Food and Drug Administration said on Friday…more

GSK’s Tykerb: OK for head and neck cancer (maybe) – New clinical data supports the use of GlaxoSmithKline’s drug Tykerb as a treatment for head and neck cancer, endorsing the company’s move to push ahead with a final Phase III study in this indication…more

UCB’s Keppra XR: OK for sale – Belgian pharma group UCB said on Monday that U.S. health authorities had approved epilepsy drug Keppra XR and that it would go on sale just before its mother drug loses patent protection…more

Impactiviti’s Recommendra: Now prescribed for all training recommendations (OK, just checking to see if you were reading…)

J&J putting some heat on Enbrel for psoriasis – Johnson & Johnson said on Thursday its experimental psoriasis drug proved more effective than top-selling treatment Enbrel in a late-stage trial, was just as safe and required far fewer injections…more

Memory Pharmaceuticalsforget about jobs for half of employees.

An interesting new avenue of diabetes research unveiled – new class of hormones produced by body fat identified.

On the pharma marketing front….

Reuters and The Doctor’s Channel collaborate for streaming video healthcare “snacking.”

On-line detailing taking off.

Reblog this post [with Zemanta]

Read Full Post »